anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Many fatal intoxications have been reported in connection with the consumption of newer, highly potent synthetic cannabinoids. Yet, a possible postmortem redistribution (PMR) might complicate reliable interpretation of analytical results. Thus, it is necessary to investigate the PMR-potential of new synthetic cannabinoids. The pig model has already proven to be suitable for this purpose. Hence, the aim of this study was to study the PMR of the synthetic cannabinoid 5F-MDMB-P7AICA and its main metabolite 5F-MDMB-P7AICA-dimethylbutanoic acid (DBA). 5F-MDMB-P7AICA (200 µg/kg body weight) was administered by inhalation to anesthetized and ventilated pigs. At the end of the experiment, the animals were euthanized and stored at room temperature for 3 days. Tissue and body fluid samples were taken daily. Specimens were analyzed after solid phase extraction using a standard addition method and LC-MS/MS, blood was quantified after protein precipitation using a validated method. In perimortem samples, 5F-MDMB-P7AICA was found mainly in adipose tissue, bile fluid, and duodenum contents. Small amounts of 5F-MDMB-P7AICA were found in blood, muscle, brain, liver, and lung. High concentrations of DBA were found primarily in bile fluid, duodenum contents, urine, and kidney/perirenal fat tissue. In the remaining tissues, rather low amounts could be found. In comparison to older synthetic cannabinoids, PMR of 5F-MDMB-P7AICA was less pronounced. Concentrations in blood also appear to remain relatively stable at a low level postmortem. Muscle, kidney, fat, and duodenum content are suitable alternative matrices for the detection of 5F-MDMB-P7AICA and DBA, if blood specimens are not available. In conclusion, concentrations of 5F-MDMB-P7AICA and its main metabolite DBA are not relevantly affected by PMR.
With advances in medical care, more youth with intellectual and/or developmental disabilities (IDD) are transitioning into adulthood. Patient- and family-centered, integrated care is warranted around this time of transition. Support teams (including the youth, caregivers, teachers, and pediatricians) should engage in transition planning, ideally starting between 12 and 14 years of age, to identify and develop resources to support the maturing youth's capacity for independent decision-making. Care teams should consider the varied levels of alternative decision-making support, which may include supported decision-making, medical proxy decision-making, power of attorney, and/or establishment of legal guardianship arrangements, to support the youth's health and well-being optimally. Ultimately, if independent decision-making is not appropriate, the goal for youth with IDD should be the least restrictive alternative, while preserving human rights and human dignity and promoting their autonomy. These considerations review alternative decision-making support, concepts, and legal requirements available for youth with IDD and their care teams. Pediatricians can support youth with IDD and their families in the transition process and decision-making autonomy by actively engaging the youth in care decisions, supporting needs for augmentative communication, fostering their expression of preferences and understanding of care decisions, and linking them to resources such as the medical-legal partnership model.
The invention provides a herbal preparation capable of treating uarthritis. The herbal medicines of the herbal preparation comprise 1 part of rubus corchorifolius, 0.2-1.1 parts of caulis clematidis armandii, 0.2-1.2 parts of anredera cordifolia, 0.2-1.2 parts of japanese polypody rhizome, 0.2-1.2 parts of sticktight, 0.2-1.2 parts of tawny daylily and 0.2-1.2 parts of the root of kudzu vine. A preparation method of the herbal preparation comprises the following steps: smashing dry products of all herbal medicines into powders with the granularity not higher than 100 meshes, and uniformly mixing the powders in proportion. A use method of the herbal preparation comprises the following steps: quantitatively subpackaging the herbal preparation into small bags by use of tea-wrappage paper bags, wherein each bag is 100g in weight; soaking the small bags with boiled water or boiling the small bags so as to be drunk, wherein during boiling, the herbal bags are put into a proper amount of boiled water, and then boiled for 5-10 minutes, then herbal soup is drunk, one bag is boiled for three times each day. The herbal preparation is developed according to the folk nostrum of the Yi nationality; on the basis of preserving the ancestral nostrum, the herbal medicines and proportions are adjusted and improved, so that the herbal composition is capable of adjusting liver and tonifying kidney, enhancing or recovering functions of internal organs of a human body, achieving the normal metabolism capability of the human body and eliminating pathogenesis. The herbal preparation is relatively rapid in uarthritis treatment effect, relatively strong in analgesia effect and relatively long in medical effect. After the herbal preparation is continuously taken for one month, theuric acid is reduced to 400-420; after the herbal preparation is continuously taken for three month, theuric acid is kept normal for a long period.
FIELD: medicine, stomatology. SUBSTANCE: the present innovation deals with blockade of affected branches of trigeminal nerve (TN) in case of its neuralgia and neuropathy. One should carry out combined blockade of TN affected branches with 20%-GHBA solution with 2%-lidocaine hydrochloride solution in one and the same syringe. Moreover, at neuropathy/neuralgia of TN first branch one should inject 0.5-1.0 ml solution into area of supraorbital nerve exit. At neuralgia/neuropathy of TN second branch 2.0 ml solution should be injected: 1.5 ml into exit area of suborbital nerve out of analogous channel and 0.5 ml into exit area of superior posterior alveolar nerves in mandibular tuber's area, or, in severe cases, according to stem anesthesia of TN second branch it is necessary to inject 2.0 ml. At neuralgia/neuropathy of TN third branch 1.5 ml solution should be injected either into area of mandibular torus or exit area of peripheral branch out of mental opening, and, also, in severe cases, 2.0 ml according to stem anesthesia of TN third branch. Course consists of 7-10 daily blockades. The present method enables to decrease dosage of local anesthetic at no risk for developing respiratory stoppage and shorten terms for staying in hospital. EFFECT: higher efficiency of therapy. 2 ex, 2 tbl
Hematologic Abnormalities

Treatment with CIBINQO was associated with an increased incidence of thrombocytopenia and lymphopenia [see Adverse Reactions (6.1)]. Prior to CIBINQO initiation, perform a CBC [see Dosage and Administration (2.1)]. CBC evaluations are recommended at 4 weeks after initiation and 4 weeks after dose increase of CIBINQO. Discontinuation of CIBINQO therapy is required for certain laboratory abnormalities [see Dosage and Administration (2.6)].

Lipid Elevations

Dose-dependent increase in blood lipid parameters were reported in subjects treated with CIBINQO [see Adverse Reactions (6.1)]. Lipid parameters should be assessed approximately 4 weeks following initiation of CIBINQO therapy and thereafter patients should be managed according to clinical guidelines for hyperlipidemia. The effect of these lipid parameter elevations on cardiovascular morbidity and mortality has not been determined.
Participants in this arm will receive cryotherapy in the form of ice pack applications to the perianal area for 20 minutes every 2 hours during the first 48 hours after hemorrhoidectomy. The ice packs will be applied externally to the surgical site to reduce pain, swelling, and inflammation. Participants will be instructed on proper ice pack application techniques and will be provided with the necessary supplies. Postoperative pain levels, analgesic consumption, wound healing, and other outcomes will be assessed at various time points.
Lactated Ringers bolus of 1000 mL will be initiated when the patient is positioned for epidural placement. A half-dose oxytocin will be initiated and not increased until 60 minutes after.
Various neurovascular free muscle transfers for smile reconstruction in patients with facial paralysis have been reported. However, these methods focused on perioral smiling rather than eye smiling. Although the lower eyelid does not contribute significantly to eyelid closure, dynamic reanimation of the upward movement of the lower eyelid with bulging of the malar region during smiling is important in smile reconstruction. The authors present a novel procedure for smiling eye and perioral smiling. The V-shaped latissimus dorsi muscle flap containing the descending branch (DB) of the thoracodorsal nerve (TDN) was used. Muscle A (15 to 17 cm), which is located along the main trunk of the DB, is much longer than muscle B (10 to 12 cm), which is along the branch of DB. A distal stump of the TDN involved in muscle B was prepared. The true trunk and distal stump of the TDN were sutured to the contralateral facial and ipsilateral masseteric nerves, respectively. The central region of muscle A was positioned at the lateral part of the lower eyelid; the distal end of long muscle A was affixed to the temporal region, which enabled periocular movements and narrowing of the palpebral fissures alongside perioral smiling when muscle A contracted. Nine patients with complete flaccid facial paralysis were treated. All patients attained muscle contraction induced by the ipsilateral masseteric and contralateral facial nerves. The smiling eye appearance was observed in 7 of 9 patients. This procedure simultaneously improves paralytic ectropion at rest and aids eyelid closure and enables early voluntary smile and a later spontaneous smile.
RATIONALE AND OBJECTIVES: We constructed a comprehensive model by combining the radiomics and clinical features of tumors to predict the recurrence risk of patients with operable stage IA-IIIA non-small cell lung cancer (NSCLC). Our aim was to improve the accuracy of prognostic prediction and provide personalized treatment plans to enhance patient outcomes.
MATERIALS AND METHODS: We retrospectively analyzed 152 surgically treated patients with pathologically confirmed stage IA-IIIA NSCLC. These patients were randomly divided into a training cohort and a test cohort in an 8:2 ratio. Using the 3D Slicer image computing platform, we manually delineated the regions of interest (ROI) for all lesions and extracted radiomics features using Python. We used the Least Absolute Shrinkage and Selection Operator (LASSO) to select the radiomics features, while the COX multivariate regression model was employed to identify independent clinical risk factors for recurrence. Finally, we utilized logistic regression (LR) to build the model and validated it using the receiver operating characteristic curve (ROC). The predictive performance of the model was evaluated using the concordance index (C-index), and the clinical value of the model was compared through decision curve analysis (DCA).
RESULTS: We extracted a total of 1562 radiomics features. After feature selection, we retained 29 features. The COX multivariate regression model demonstrated that the N stage was an independent risk factor for postoperative recurrence. In the training and test cohorts, the area under the curve (AUC) values of the radiomics-clinical comprehensive model were 0.972 and 0.937, respectively, while the C-index values were 0.815 and 0.847. These values surpassed those of the standalone clinical model or radiomics model.
CONCLUSION: Our study demonstrates that a comprehensive model based on CT radiomics and clinical features can effectively stratify the risk of postoperative recurrence in patients with operable NSCLC. It provides a powerful tool for accurately stratifying the risk of high-risk patients after surgery.
The invention discloses a Kazak traditional drug combination for curing qi and blood-blocked hypertension and a preparation method of the Kazak traditional drug combination. The Kazak traditional drug combination combines a six yuan theory namely an ozeg alta turor theory, a qi, function and energy theory namely a huwati theory, a body fluid theory namely sule theory, an organ theory namely a muxielieer theory and the like in the traditional medicine theory basis Introduction to Kazakh Medicine, and mainly aims at preventing and curing qi and blood-blocked hypertension. Kazak traditional medicinal materials such as the root of red-rooted salvia, red flower, rhizoma alismatis, lumbricus, scorpion, bighead atractylodes rhizome, ligusticum wallichii, semen cassiae torae, wild chrysanthemum flower, loranthus parasiticus, peach kernel and uncaria are selected, are subjected to water extraction and ethanol extraction, and are uniformly mixed to form raw materials to prepared into a preparation for oral administration. The forms of preparation comprise all forms of preparation for oral administration, such as granules, powder, pills, capsules, tablets, and oral liquid, which are suitable for clinically preventing and curing hypertension. The Kazak traditional drug combination has a better curative effect especially for adjuvant therapy for qi and blood-blocked hypertension. The Kazak traditional drug combination has the advantages of reasonable formula, convenience in preparation, significant curative effect, fast becoming effective and no irritating toxic or side effects.
Technique 1Lateral orbicularis and corrugator injections: 5 equally spaced injections will be placed intramuscularly into the orbicularis under the lateral eyebrow starting lateral to the level of the lateral limbus and extending to the level of the inferior orbital rim. In addition, 2 injections will be placed 1cm apart into the corrugator starting at the medial brow and extending laterally. Then 5 equally spaced injections, in a V pattern will be placed in the frontalis. The first injection between the medial brows, 2 injection 1cm below the hairline at the level of the lateral canthus and one injection equidistant to medial and lateral injection.
Patients receive PI3K inhibitor BYL719 PO QD and letrozole PO QD. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
Placebo will be administered at a dose of 10mg/day orally once a day. One cycle of therapy consists of 28 days.The patients also receive the best supportive care.
In addition to core UP-A preventive intervention, PROCARE + will apply an innovative personalized medicine approach by adding specific modules according to the risk factor evidenced by adolescents. Different modules will be suited for the stratified groups in a more personalized format. Add-on young-focused modules would include: rejection, bullying/cyberbullying, addictions, healthy lifestyle habits, exam stress management, ecoanxiety, parental expressed emotion. A booster sessions would be included at 6 months.
The enhanced curriculum of 108 hours of home health aide (HHA) training will constitute the Experimental arm. This arm consists of the 100 hours of the standard curriculum plus an 8-hour enhanced curriculum that includes additional didactic content and a skills practicum on dementia and recognizing and responding to dementia-related behaviors. As with the standard curriculum, the enhanced curriculum will be delivered by the training entity, CCHERS (Center for Community Health Education, Research and Service, Inc.). The enhanced component is delivered over an additional 2 instructional days (10% increase in instructional days from the standard curriculum).
Should there be no DLT under PIPAC arm at Paclitaxel 15mg/m2, recruitment at ePIPAC 15mg/m2 and PIPAC 30mg/m2 will occurs concurrently in an alternating fashion. PIPAC/ePIPAC dose escalation will continue until a MTD has been reached. Should there be no DLT at PIPAC 30mg/m2 and ePIPAC 15mg/m2, recruitment at PIPAC 45mg/m2 and ePIPAC 30mg/m2 will occurs concurrently in an alternating fashion. Finally, should there be no DLT, recruitment at ePIPAC 45mg/m2 will occurs.
Placebo, 2 pills, oral, twice daily for 7 days. To be taken with food.
<P>PROBLEM TO BE SOLVED: To provide a highly effective composition for removing abnormal protein and to provide compositions, agents and foods contributing to prophylaxis and treatment, etc., of diseases caused by the abnormal protein decomposition.  <P>SOLUTION: The invention relates to the composition for removing abnormal protein comprising a soybean saponin group B as a principal component. The soybean saponin group B is a composition for removing abnormal protein characterized by preferably containing 40-100 pts.wt. of the soybean saponin group B per 100 pts.wt. of soybean extract.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Subjects will maintain the standard diet and will perform resistance exercise sessions in the fed state, between 1 and 2 hours after consuming a carbohydrate-containing meal. Over the 12 weeks of intervention, participants will perform two sessions a week of resistance exercises.
An isolated complex comprising a NNT-1 protein and a CLF-1 and/or sCNTFRalpha protein, is new. Also claimed are (i) a vector, or system of 2 or 3 co-expression vectors, comprising a nucleic acid sequence encoding NNT-1, and a sequence encoding CLF-1 and/or a sequence encoding sCNTFRalpha (ii) a cell comprising the above vector, preferably eukaryotic, more preferably mammalian (iii) preparing the claimed complex using the above vectors or cells (iv) preparing the claimed complex, comprising culturing a cell comprising DNA encoding NNT-1, and DNA encoding CLF-1 and/or DNA encoding sCNTFRalpha , under expression conditions, and recovering the complex formed from the culture medium or cell lysate (v) preparing the claimed complex, comprising (a) culturing cells comprising DNA encoding NNT-1 and cells comprising DNA encoding CLF-1, and/or cells comprising DNA encoding sCNTFRalpha (b) contacting NNT-1 and CLF-1 and/or sCNTFRalpha obtained from the respective mediums or cell lysates, and (c) recovering the complex formed (vi) complexes obtained using the above methods (vii) a NNT-1/CLF-1 complex capable of binding to the CNTFRalpha receptor (viii) a NNT-1/sCNTFRalpha complex capable of binding to the LIFRbeta receptor (ix) polyclonal or monoclonal antibodies, or their fragments or derivatives specific for an NNT-1/CLF-1, an NNT-1/CLF-1/sCNTFRalpha or an NNT-1/sCNTFRalpha complex ACTIVITY : Cytostatic; Gynecological; Nootropic; Anticonvuslatant; Anorectic; Antiparkinsonian. MECHANISM OF ACTION : Signal transduction. BAF/3 cells transfected with cDNAs encoding CNTFRalpha , gp130 and LIFRbeta were exposed to the NNT-1/CLF-1 complex, resulting in phosphorylation of LIFRbeta not seen in controls. Similarly phosphorylation of gp130 and LIFRbeta was induced in SK-N-MC known to express CNFR A, gp130 and LIFRbeta . No hard data is given.
Lipidated analogs of prolactin-releasing peptides (PrRP) and their use in controlling and lowering blood glucose in mammals is disclosed. Useful compounds included lipidated analogs of PrRP20 and PrRP31. Pharmacological effects are demonstrated both in vitro and in vivo. Peripheral administration of the lipidated peptides lowers blood glucose levels. These treatments are applicable for treating impaired glucose tolerance (IGT), and glucose intolerance condition. The disclosed compounds have application in treating medical conditions including diabetes, pre-diabetes, eating disorders, and obesity.
Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide. Accurate cancer risk assessment approaches could increase rates of early CRC diagnosis, improve health outcomes for patients and reduce pressure on diagnostic services. The faecal immunochemical test (FIT) for blood in stool is widely used in primary care to identify symptomatic patients with likely CRC. However, there is a 6-16% noncompliance rate with FIT in clinic and ~90% of patients over the symptomatic 10 µg/g test threshold do not have CRC. A polygenic risk score (PRS) quantifies an individual's genetic risk of a condition based on many common variants. Existing PRS for CRC have so far been used to stratify asymptomatic populations. We conducted a retrospective cohort study of 50,387 UK Biobank participants with a CRC symptom in their primary care record at age 40+. A PRS based on 201 variants, 5 genetic principal components and 22 other risk factors and markers for CRC were assessed for association with CRC diagnosis within 2 years of first symptom presentation using logistic regression. Associated variables were included in an integrated risk model and trained in 80% of the cohort to predict CRC diagnosis within 2 years. An integrated risk model combining PRS, age, sex, and patient-reported symptoms was predictive of CRC development in a testing cohort (receiver operating characteristic area under the curve, ROCAUC: 0.76, 95% confidence interval: 0.71-0.81). This model has the potential to improve early diagnosis of CRC, particularly in cases of patient noncompliance with FIT.
The combined use of fenofibrate and HMG-CoA reductase inhibitors should be avoided unless the benefit of further alterations in lipid levels is likely to outweigh the increased risk of this drug combination.

Concomitant administration of fenofibrate (equivalent to fenofibrate 200 mg) and pravastatin (40 mg) once daily for 10 days increased the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3α-hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively. (See also CLINICAL PHARMACOLOGY, Drug-drug Interactions.)

The combined use of fibric acid derivatives and HMG-CoA reductase inhibitors has been associated, in the absences of a marked pharmacokinetic interaction, in numerous case reports, with rhabdomyolysis, markedly elevated creatine kinase (CK) levels and myoglobinuria, leading in a high proportion of cases to acute renal failure.

The use of fibrates alone, including fenofibrate capsules may occasionally be associated with myositis, myopathy, or rhabdomyolysis. Patients receiving fenofibrate and complaining of muscle pain, tenderness, or weakness should have prompt medical evaluation for myopathy, including serum creatine kinase level determination. If myopathy/myositis is suspected or diagnosed, fenofibrate therapy should be stopped.
Mycophenolate mofetil and tacrolimus (MMF) treatment arm: MMF dose was initiated at 1 g b.i.d. (2 g/day). Adjustments were to be made for adverse events including, but not limited to, gastrointestinal intolerance and decrease in WBC. MMF trough or AUC was not used to adjust dosing. In this group, tacrolimus was initiated according to local practice. Tacrolimus dose was adjusted from Day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 12 ng/mL. From Month 2 until Month 6, target tacrolimus trough level was reduced to 7 - 10 ng/mL. After Month 6, target level of tacrolimus was reduced to 5 - 8 ng/mL.
Conventional treatment: Neonates will be placed in an incubator (Ningbo David Medical Device Co., LTD, XHZ model) at 30℃ and relative humidity at 55%. Throughout the study, exclusive breastfeeding and professional care will be provided for the newborns. Newborns requiring phototherapy receive it in the following manner: Phototherapy eye masks (Foshan Forman Medical Technology Co., LTD., Yuesun Mechanical Equipment No. 20160015) and phototherapy diapers (Foshan Baojusheng Medical Equipment Co., LTD., GB/T33280) will be used to cover the eyes and perineum, respectively. Phototherapy was provided via LED blue light continuous irradiation with a wavelength of 425-475nm. All treated neonates will receive continuous phototherapy for 12 hours, then allowe to rest for 6-8 hours, then receive another 12 hours of continuous phototherapy. The decision to continue with further treatment depends on changes in the neonate's jaundice.